Publicaciones en las que colabora con GUILLERMO MARIA LOPEZ VIVANCO (21)

2021

  1. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  2. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

  3. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553

  4. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890

2020

  1. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  2. Germline c.1A>C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): A case report

    Hereditary Cancer in Clinical Practice, Vol. 17, Núm. 1

2018

  1. Aportación del uso medicinal de los derivados del cannabis: una revisión de su potencial eficacia clínica y riesgos

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 115, Núm. 2, pp. 83-95

  2. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

  3. Contribution of the medicinal use of cannabis derivatives: A review of their potential clinical efficacy and risks

    Gaceta Medica de Bilbao, Vol. 115, Núm. 2, pp. 83-95

  4. Infective endocarditis in a patient with metastatic colorectal cancer

    Revista Espanola de Quimioterapia

  5. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study

    OncoTargets and Therapy, Vol. 11, pp. 5845-5852

2017

  1. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

    Journal of the National Cancer Institute, Vol. 109, Núm. 9

  2. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1454-1461

  3. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: What is our clinical practice?

    European Journal of Gynaecological Oncology, Vol. 38, Núm. 5, pp. 695-699

  4. Hereditary pancreatic cancer: Related syndromes and clinical perspective

    Hereditary Cancer in Clinical Practice, Vol. 15, Núm. 1

2015

  1. Coste del tratamiento del cáncer de mama por estadío clínico en el País Vasco

    Revista Espanola de Salud Publica, Vol. 89, Núm. 1, pp. 93-97

  2. Supervised physical exercise to improve the quality of life of cancer patients: The Eficancer randomised controlled trial

    BMC Cancer, Vol. 15, Núm. 1

2012

  1. Identification of a biomarker panel for colorectal cancer diagnosis

    BMC Cancer, Vol. 12

2003

  1. Incidencia y mortalidad del cáncer. Historia natural

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 100, Núm. 4, pp. 139-143